Effect of Integrated Dual-Task Trunk Stabilization and Balance Training in Sedentary Adult Females

May 20, 2026 updated by: Nesma Morgan Allam, Cairo University

Effect of Integrated Dual-Task Trunk Stabilization and Balance Training on Balance, Trunk Muscle Activation, and Visual-Motor Integration Performance in Sedentary Adult Females: A Randomized Controlled Trial

Balance and postural control are fundamental components of functional independence and quality of life in adults. Deficits in trunk stability and balance are strongly associated with increased fall risk, impaired mobility, and decreased ability to perform activities of daily living in sedentary individuals and clinical populations. Trunk muscles play a key role in stabilizing the spine and coordinating movement; their activation is essential for maintaining balance during static and dynamic tasks. Evidence suggests that targeted trunk training can significantly improve postural control and functional outcomes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
58

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Egypt
      • Giza, Egypt
        • Recruiting
        • Faculty of Physical Therapy, Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants with low physical activity level evaluated by the Arabic version of the International Physical Activity Questionnaire-Short Form.
  • Their age between 18 and 30 years.
  • Body mass index less than 30 kg/ m2
  • Participants who did not engage in a physiotherapy program in the previous 6 months.
  • Have the ability to stand independently on balance board.
  • With good cognition.
  • No prior experience with dual task training.
  • Absence of visual impairments, injuries or medications (such as analgesics or muscle relaxants) that may affect the results of the study.

Exclusion Criteria:

  • Any neurological diseases (such as; severe disc prolapse and radiating pain). - History of knee injury.
  • Fracture or surgery in lower extremity or the spine.
  • Congenital deformity.
  • Orthopedic disorders such as patellofemoral pain syndrome.
  • Vestibular disorders or severe balance impairment.
  • Psychiatric problem.
  • Any systemic disease.
  • Cardiovascular complications.
  • Pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Study group (Multitask group)
Participants will receive multi-task training including strength, balance training, and visual-motor task simultaneously.
Other: Multi-task training
Participants will be instructed to hold standardized handheld weight (adjusted according to individual tolerance) with both hands at chest level throughout the task to provide an additional upper-body strength component and increase trunk muscle engagement. During training, visual stimuli will be presented on a monitor positioned at eye level at approximately 1.5 m. Four geometric symbols (square, triangle, circle, and star) will be randomly displayed on the screen, each corresponding to a specific trunk movement direction.
Active Comparator: Control group (Single task group)
Participants will receive a single task including strength, balance training, and visual-motor task separately.
Other: Single task
Participants will perform the same balance, strength, and cognitive components separately to eliminate task integration effects.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Time Up and Go test
Time Frame: 4 weeks
Time Up and Go test will be used to evaluate dynamic balance. Participants will be asked to rise from a chair, walk 3 m to the line on the floor at a normal pace, turn around, walk back to the chair, and sit down. The time will be calculated using stopwatch. The greater the time spent to complete the test the greater the risk of impaired balance. While less time reflects good balance and mobility.
4 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Single leg stance test
Time Frame: 4 weeks
Single leg stance test will be used to assess static balance performance. Participants will be asked to stand on the dominant leg for as long as possible with their eyes closed and arms on the hips. Three measurements will be performed from the time the foot left the floor until it touches the ground. The mean of all three measurements will be used for analysis. Greater time indicated good static balance and less time indicates low static balance.
4 weeks
Visual-Motor integration
Time Frame: 4 weeks
Participants will be instructed to stand upright facing a monitor at eye level and respond to four randomly presented visual symbols. The following visual-motor performance variables will be calculated; the reaction time which is the time interval between stimulus onset and the initiation of trunk movement. Also, response accuracy (%) will be determined by dividing the number of correct responses by the total number of presented stimuli and multiplying by 100.
4 weeks
Trunk muscle activity
Time Frame: 4 weeks
The Delsys electromyography (EMG) system will be used to record muscle activity at the sampling rate of 2000 Hz. Eight EMG sensors will be placed on the torso of the participant to determine muscle activation. Electrodes will then be fixed to the skin using specially designed adhesive interfaces. Following EMG placement, maximum voluntary contraction will be performed to determine the maximum muscle activation level for each muscle.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 20, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 20, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 12, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 12, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 18, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 053-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings